BIBW 2992（Tovok）肺癌新药

张玉强 · 发表于 2013-8-22 20:54:14

2个月2292就耐药，有点担心！

张玉强 · 发表于 2013-8-22 20:55:08

谁知道，YL2992与正版的阿法替尼有多大差别？

张玉强 · 发表于 2013-8-22 22:12:34

找找中药，可能不到调理有用，病情有稳定。

岁月匆匆 · 发表于 2013-9-6 14:35:20

一定要做好准备,一是做好对副作用的应对;二是做好YL版的混装;三是要多了解靶向药的知识;四是多备几种靶向药,感谢憨叔和老马!

老马 · 发表于 2013-9-11 01:19:52

LUX-LUNG 4
The phase II LUX-LUNG 4 trial gives further support to the idea that afatinib may be a good option for patients who develop that T790M resistance mutation following treatment with other TKIs. Researchers led by Nobuyuki Katakami, MD, PhD, of Kobe City Medical Center General Hospital in Kobe, Japan, treated 62 patients who were EGFR-mutation positive in the primary tumor with afatinib at 50 mg/day. Fifty-one of the patients (82.3%) qualified as having acquired resistance to erlotinib and/or gefitinib.

Of the 61 patients who were evaluable, five (8.2%) had a confirmed objective response to afatinib. The median progression-free survival was 4.4 months, with a median overall survival of 19 months. Among the afatinib-related adverse events, all patients experienced diarrhea and most (91.9%) had rash/acne; 29% of patients had an adverse event that led to discontinuation of the drug.

“The results of our trial demonstrated modest but noteworthy activity of afatinib in this difficult-to-treat population,” the authors wrote. They noted that further trials are now ongoing, including one phase IB trial testing the combination of afatinib and cetuximab(Drug information on cetuximab) in a small number of patients. “There is an increasing need to develop new molecular targeted agents that address the issue of resistance to erlotinib and/or gefitinib in patients with NSCLC who initially respond to treatment and then subsequently progress.”